Is compounded semaglutide dangerous?

The class effects of semaglutide apply to any preparation of it. The additional risks of compounding come from dosing errors with vials, quality variation between pharmacies, and ingredient sourcing. FDA has reported adverse events including dosing errors with compounded GLP-1s; the size of the risk cannot be quantified from public data.

Published August 27, 2026 · updated August 27, 2026 · regulatory and clinical facts last checked 2026-08-27 · medically reviewed by Dr. S. Shuwart, MD on August 27, 2026

Medically reviewed · August 27, 2026

Compounded GLP-1 safety: what is known, what is not

What can and cannot be said about the safety of compounded semaglutide and tirzepatide: the class effects that carry over, the risks that are specific to compounding, and what FDA has reported.

What carries over from the approved products

The pharmacology is the same molecule. Gastrointestinal effects during dose escalation, the labelled warnings (pancreatitis, gallbladder disease, hypoglycaemia with certain diabetes medicines, acute kidney injury with dehydration, the thyroid C-cell boxed warning and its contraindications) and the drug-interaction considerations apply to a compounded preparation of semaglutide or tirzepatide as they do to the approved product. None of this is reduced by compounding.

What is specific to compounding

Dosing errors. Approved pens deliver a fixed dose. Compounded vials are drawn by volume from a concentration chosen by the pharmacy, and concentrations differ between pharmacies and between batches. FDA has reported adverse events linked to patients drawing the wrong volume, sometimes many times the intended dose, and to confusion between units on syringes. This is the most concrete compounding-specific risk in the public record.

Quality variation. No agency tests the finished product before sale. Sterility, potency and stability depend on the pharmacy’s processes, its adherence to USP standards, and its state board’s oversight, or on FDA inspection for 503B facilities. Warning letters and inspection findings for specific facilities are public and are recorded on pharmacy profiles here when we have checked them.

Ingredient sourcing. The active ingredient must come from a registered supplier and be the correct substance. FDA’s statements about semaglutide salt forms are the clearest example of what can go wrong.

Additives. Vitamin B12, B6, glycine, niacinamide and L-carnitine appear in some preparations. None has trial evidence with these drugs, and each adds a variable to the formulation.

Beyond-use dates. A multi-dose vial has a beyond-use date assigned by the pharmacy; using it beyond that date, or storing it incorrectly, is a risk the approved pens’ packaging does not carry in the same way.

What is not known

There is no controlled trial of any compounded GLP-1 preparation, so the efficacy and safety of the compounded product relative to the approved one is not established; it is inferred from the molecule. Adverse-event reports to FDA cannot give a rate because the denominator of patients using compounded products is unknown.

What this site records

For each provider: whether it states that compounded products are not FDA-approved; whether it names the pharmacy and its type; whether the form of the active ingredient, the concentration and the beyond-use date are disclosed; and whether it includes instructions for drawing the dose. The Compounding Disclosure Index scores the disclosures.

Questions this page answers

Is compounded semaglutide dangerous?: The class effects of semaglutide apply to any preparation of it. The additional risks of compounding come from dosing errors with vials, quality variation between pharmacies, and ingredient sourcing. FDA has reported adverse events including dosing errors with compounded GLP-1s; the size of the risk cannot be quantified from public data.

Sources

FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (regulator)
Zepbound and Wegovy prescribing information (warnings and precautions) (label)
USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations (standard)

Educational information, not medical advice. Decisions about GLP-1 medication belong with you and a licensed clinician who knows your history. Compounded medications are not FDA-approved. Report an error.